跳至主要内容
临床试验/NCT05258461
NCT05258461Unknown不适用

An Innovative Smartphone Application for Adverse Event Management During Breast Cancer Adjuvant Chemotherapy: a Randomized Controlled Trial

Peking Union Medical College Hospital0 个研究点目标入组 108 人开始时间: 2022年3月7日最近更新:
适应症

试验速览

阶段
不适用
入组人数
108
主要终点
Change from baseline quality of life scores at 4 months

研究概览

简要总结

The aim of this study is to evaluate benefits of the app in breast cancer patients receiving the docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy. The investigators hypothesized that the addition of the app to conventional adverse event management would increase quality of life (QoL) scores and reduce adverse events.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • pathological diagnosis of invasive breast cancer
  • breast surgery within the past 2-8 weeks
  • adult female
  • must be able to use mobile phones
  • speak and write Chinese fluently to sign the informed consent

排除标准

  • severe comorbidity that interferes with outcome evaluation
  • insufficient Chinese language skills
  • inability to use mobile phones
  • cognitive disability to give informed consent

结局指标

主要结局

Change from baseline quality of life scores at 4 months

时间窗: 1 day before the first cycle, and 4 months after the first cycle (each cycle is 21 days)

Quality of life scores will be assessed using the simplified Chinese version of the Organization for Research and Treatment of Cancer (EORTC QLQ-C30, version 3).

次要结局

  • Incidence and severity of 12 common adverse events(4 months after the first cycle (each cycle is 21 days))

研究者

申办方类型
Other
责任方
Sponsor

相似试验